NEW YORK — French diagnostics firm HalioDx said on Thursday that it has signed an agreement for the distribution of its Immunoscore colon cancer risk-assessment test in Brazil with Diagnosticos da America (DASA).
According to HalioDx, Immunoscore is designed to predict the risk of relapse in early-stage colon cancer by measuring host immune responses at tumor sites, helping to guide treatment strategies.